Hyundai Pharmaceutical Co., Ltd. (004310.KS)
KRW 3710.0
(-2.62%)
KRW 3710.0
(-2.62%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 39.2 Billion KRW | -0.6% |
| 2022 | 39.44 Billion KRW | 32.16% |
| 2021 | 29.84 Billion KRW | 21.21% |
| 2020 | 24.62 Billion KRW | 17.25% |
| 2019 | 21 Billion KRW | 0.0% |
| 2018 | 21 Billion KRW | -28.7% |
| 2017 | 29.45 Billion KRW | 9.35% |
| 2016 | 26.93 Billion KRW | 28.27% |
| 2015 | 21 Billion KRW | 11.92% |
| 2014 | 18.76 Billion KRW | -9.57% |
| 2013 | 20.74 Billion KRW | -29.15% |
| 2012 | 29.28 Billion KRW | 46.43% |
| 2011 | 20 Billion KRW | -9.09% |
| 2010 | 22 Billion KRW | -6.47% |
| 2009 | 23.52 Billion KRW | 23.79% |
| 2008 | 19 Billion KRW | 0.0% |
| 2007 | - KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 39.17 Billion KRW | -0.09% |
| 2024 Q3 | 42.66 Billion KRW | 1.42% |
| 2024 Q2 | 42.78 Billion KRW | 9.23% |
| 2023 Q2 | 38.49 Billion KRW | -2.78% |
| 2023 Q1 | 39.6 Billion KRW | 0.41% |
| 2023 FY | 39.2 Billion KRW | -0.6% |
| 2023 Q4 | 39.2 Billion KRW | 0.44% |
| 2023 Q3 | 39.03 Billion KRW | 1.39% |
| 2022 Q2 | 39.67 Billion KRW | 32.38% |
| 2022 Q3 | 39.58 Billion KRW | -0.24% |
| 2022 FY | 39.44 Billion KRW | 32.16% |
| 2022 Q4 | 39.44 Billion KRW | -0.36% |
| 2022 Q1 | 29.97 Billion KRW | 0.43% |
| 2021 Q2 | 37.15 Billion KRW | 51.22% |
| 2021 Q3 | 39.75 Billion KRW | 7.0% |
| 2021 Q4 | 29.84 Billion KRW | -24.93% |
| 2021 FY | 29.84 Billion KRW | 21.21% |
| 2021 Q1 | 24.57 Billion KRW | -0.21% |
| 2020 Q4 | 24.62 Billion KRW | 0.32% |
| 2020 FY | 24.62 Billion KRW | 17.25% |
| 2020 Q3 | 24.54 Billion KRW | -0.2% |
| 2020 Q2 | 24.59 Billion KRW | 13.51% |
| 2020 Q1 | 21.66 Billion KRW | 3.17% |
| 2019 Q3 | 21 Billion KRW | 0.0% |
| 2019 Q1 | 21 Billion KRW | 0.0% |
| 2019 Q2 | 21 Billion KRW | 0.0% |
| 2019 Q4 | 21 Billion KRW | 0.0% |
| 2019 FY | 21 Billion KRW | 0.0% |
| 2018 Q1 | 24.02 Billion KRW | -18.43% |
| 2018 FY | 21 Billion KRW | -28.7% |
| 2018 Q4 | 21 Billion KRW | -1.32% |
| 2018 Q3 | 21.28 Billion KRW | -3.31% |
| 2018 Q2 | 22 Billion KRW | -8.39% |
| 2017 Q2 | 28.78 Billion KRW | 6.61% |
| 2017 FY | 29.45 Billion KRW | 9.35% |
| 2017 Q4 | 29.45 Billion KRW | -1.8% |
| 2017 Q3 | 29.99 Billion KRW | 4.18% |
| 2017 Q1 | 27 Billion KRW | 0.25% |
| 2016 Q1 | 18.78 Billion KRW | -10.54% |
| 2016 FY | 26.93 Billion KRW | 28.27% |
| 2016 Q3 | 23.27 Billion KRW | 6.68% |
| 2016 Q4 | 26.93 Billion KRW | 15.74% |
| 2016 Q2 | 21.81 Billion KRW | 16.12% |
| 2015 Q3 | 18.8 Billion KRW | 9.95% |
| 2015 Q2 | 17.1 Billion KRW | -6.78% |
| 2015 Q1 | 18.34 Billion KRW | -2.24% |
| 2015 FY | 21 Billion KRW | 11.92% |
| 2015 Q4 | 21 Billion KRW | 11.7% |
| 2014 FY | 18.76 Billion KRW | -9.57% |
| 2014 Q4 | 18.76 Billion KRW | 4.24% |
| 2014 Q3 | 18 Billion KRW | 0.0% |
| 2014 Q1 | 19.56 Billion KRW | -5.73% |
| 2014 Q2 | 18 Billion KRW | -7.98% |
| 2013 Q3 | 22.19 Billion KRW | 3.97% |
| 2013 FY | 20.74 Billion KRW | -29.15% |
| 2013 Q4 | 20.74 Billion KRW | -6.53% |
| 2013 Q1 | 26.83 Billion KRW | -8.36% |
| 2013 Q2 | 21.35 Billion KRW | -20.44% |
| 2012 Q4 | 29.28 Billion KRW | 0.0% |
| 2012 Q1 | 24.93 Billion KRW | 24.69% |
| 2012 FY | 29.28 Billion KRW | 46.43% |
| 2011 FY | 20 Billion KRW | -9.09% |
| 2011 Q4 | 20 Billion KRW | 0.0% |
| 2011 Q3 | 20 Billion KRW | -9.09% |
| 2011 Q2 | 22 Billion KRW | 0.0% |
| 2011 Q1 | 22 Billion KRW | 0.0% |
| 2010 Q4 | 22 Billion KRW | 0.0% |
| 2010 Q1 | 23 Billion KRW | -2.22% |
| 2010 Q3 | 22 Billion KRW | -6.26% |
| 2010 FY | 22 Billion KRW | -6.47% |
| 2010 Q2 | 23.46 Billion KRW | 2.04% |
| 2009 Q2 | 23 Billion KRW | 43.75% |
| 2009 Q4 | 23.52 Billion KRW | 2.27% |
| 2009 Q3 | 23 Billion KRW | 0.0% |
| 2009 Q1 | 16 Billion KRW | -15.8% |
| 2009 FY | 23.52 Billion KRW | 23.79% |
| 2008 Q2 | 11.51 Billion KRW | 283.85% |
| 2008 Q3 | 16.78 Billion KRW | 45.76% |
| 2008 Q1 | 3 Billion KRW | 0.0% |
| 2008 FY | 19 Billion KRW | 0.0% |
| 2008 Q4 | 19 Billion KRW | 13.21% |
| 2007 Q2 | - KRW | 0.0% |
| 2007 Q3 | - KRW | 0.0% |
| 2007 Q1 | - KRW | 0.0% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q4 | - KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 39.4 Billion KRW | 0.513% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 94.334% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 89.739% |
| HANDOK Inc. | 300.01 Billion KRW | 86.932% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | -27.861% |
| Yuhan Corporation | 230.07 Billion KRW | 82.96% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | 90.36% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -6483.686% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 93.156% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -2937.893% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 53.963% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | 9.401% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | 56.671% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | -47.759% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | 0.513% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -16363.937% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | 82.58% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | 78.34% |
| JW Holdings Corporation | 554.58 Billion KRW | 92.931% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | 82.003% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | 82.16% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 76.976% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | 15.052% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | 77.709% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | 53.858% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | 0.513% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 83.362% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 91.653% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 76.976% |
| Yuhan Corporation | 230.07 Billion KRW | 82.96% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | 77.342% |
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | 41.382% |
| Suheung Co., Ltd. | 467.85 Billion KRW | 91.62% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 76.976% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | 66.954% |
| Korea United Pharm Inc. | 40.33 Billion KRW | 2.811% |
| CKD Bio Corp. | 146.92 Billion KRW | 73.317% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | 73.156% |
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | 18.755% |
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -6103.059% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | 15.052% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 91.623% |
| Boryung Corporation | 204.21 Billion KRW | 80.802% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | 50.615% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 53.963% |
| JW Lifescience Corporation | 46.31 Billion KRW | 15.348% |